HUMAN VACCINE RESEARCH

ALLOY IS OUR ALLY

We exist to create vaccines so people can enjoy life more fully

ANTIMICROBIAL RESISTANCE

Antibiotics were the single most important medical advance of the 1900s, but almost immediately, resistant bacteria emerged and have continued to spread. In contrast, vaccines provide lasting protection against bacteria without the risk of resistance.

URINARY TRACT INFECTIONS

Urinary tract infections (UTI) are responsible for more antimicrobial use globally than any other human disease. A vaccine to prevent UTI would greatly reduce the use of antimicrobials, which will extend their usefulness to protect against other infections.

ALLOY VACCINE PLATFORM

Syntiron’s ALLOY Vaccine Platform targets multiple bacterial iron receptors to generate vaccines that are strong, broadly protective and easy to make. Syntiron’s first ALLOY Vaccine targets UTI. ALLOY is our ALLY against antimicrobial resistant bacteria. 

CARB-X IS FUNDING SYNTIRON

CARB-X IS FUNDING SYNTIRON TO DEVELOP A MATERNAL VACCINE TO PREVENT NEONATAL SEPSIS

 “CARB-X is excited to support the development of Syntiron’s maternal vaccine to help prevent neonatal sepsis, the leading cause of death among infants, especially those located in low- and middle-income countries …”

 ANTIMICROBIAL RESISTANCE IMPACTS ALL OF US 

A GROWING GLOBAL PANDEMIC

  • Common diseases are becoming untreatable and lifesaving medical procedures are riskier to perform due to AMR.
  • 35-90% of infections are due to resistant bacteria worldwide.
  • AMR infections are projected to surpass cancer as a leading cause of death worldwide (>10M) by 2050. 
  • The impact on the global gross domestic product is estimated at 100 trillion USD by 2050.

AMR vaccines are needed

  • Vaccine development for bacteria was deprioritized after the discovery of antibiotics, so relatively few bacterial vaccines are currently available.
  • Long term, vaccines are the most reliable and economically feasible option to address AMR.
  • Syntiron’s ALLOY Platform can be used to develop the AMR vaccines that are needed to save lives in every age group throughout the planet, starting with UTI.

UTI vaccine: an AMR priority

  • Urinary tract infections result in more antimicrobial use globally than any other disease.
  • UTIs are becoming more difficult to treat due to AMR.
  • At least 30% of people will experience UTI at least once during their lifetime.
  • A UTI vaccine will dramatically reduce antimicrobial use and protect against serious invasive infections caused by untreatable AMR bacteria.

Syntiron’s Alloy Vaccine Platform targets multiple bacterial metal transport proteins to generate synthetic protein vaccines that are strong, broadly protective, and easy to make.

 

OUR TECHNOLOGY

The superior strength of steel comes from the combination of iron and carbon. Steel is an alloy: a metal that is stronger than its individual parts.

Syntiron’s ALLOY Vaccine Platform leverages the same principal to combine multiple bacterial components, especially metal receptors, to enhance strength and durability. The resulting ALLOY vaccines are simple to manufacture, induce multiple arms of immunity and target a broad range of bacteria strains.  The ALLOY Vaccine Platform is our ALLY against AMR.

ABOUT

In simple terms, we are a human vaccine research firm, however, that doesn’t tell the whole story. We are a small team with a common vision, and with a collective effort we are able to accomplish big things more quickly than most vaccine research firms.

AMR RESOURCES

WORLD HEALTH ORGANIZATION

The WHO provides a gateway to information and action related to antimicrobial resistance throughout the world.

LEARN MORE

VACCINES FOR AMR

The Boston Consulting Group and Wellcome Trust maintain this site with updated comparative data on bacterial infections, target markets and vaccine development.

LEARN MORE

CIDRAP@UNIVERSITY OF MINNESOTA

The Center for Infectious Disease Research and Policy at the University of Minnesota, in our own backyard, is a worldwide resource for identifying and addressing AMR.

LEARN MORE

CENTERS FOR DISEASE CONTROL AND PREVENTION

The CDC in the USA collects the latest data and policy information for healthcase providers and citizens related to AMR. Their tracking includes AMR development and investment maps.

LEARN MORE

It makes good scientific sense to make a vaccine against [bacterial] proteins that bond with iron.

Dr. Gregory Poland, M.D., Director of Mayo Clinical Vaccine Research Group

Address

1000 Westgate Drive
St Paul MN 55114

Phone

651-641-2876

Email

info@syntiron.com